Earlier this month, the company launched its new five-Year Strategy, called Alnylam P5x25, for its planned transition to be among the top-five biotechs by market capitalization over the next five years. The company also announced full-year 2020 preliminary global net product revenues for ONPATTRO® and GIVLAARI® at nearly $306 million and $55 million, respectively.

Analysts expect revenue for the quarter ended December 31, 2020, to rise 104.5% year-over-year to $146.6 million. Meanwhile, its EPS is likely to expand at the rate of 46.1% per annum over the next five years.

ALNY ended yesterday’s trading session at $168.41, climbing 41.7% over the past year. During the past six months, the stock has risen 6.4%.

ANLY is rated “Strong Buy” with an “A” for Trade Grade, Buy & Hold Grade, Peer Grade, and a “B” for Industry Rank. It is currently ranked #6 of 483 stocks in the Biotech Industry.

Zai Lab Limited (ZLAB - Get Rating)

ZLAB is a biotechnology company involved in discovering, developing, licensing, and commercializing proprietary therapeutics to provide treatment in oncology, infectious, and l  autoimmune diseases in China.  The company’s oral small molecule poly ADP ribose polymerase 1/2 inhibitor, Niraparib, is used to treat multiple solid tumors and ovarian and lung cancer.

ZLAB announced the expansion of its collaboration with Turning Point Therapeutics (TPTX), a precision oncology company. Under the agreement, ZLAB would obtain exclusive rights to develop and commercialize TPTX’s MET, SRC, and CSF1R inhibitor, TPX-0022, in Greater China. TPTX will receive a $25 million upfront payment, with up to nearly $336 million in potential development, regulatory, and sales-based milestone payments.

For the six months ended June 2020, ZLAB’s revenue has surged 461.8% year-over-year to $19.2 million, driven by the sales of ZEJULA, which was launched in January 2020. Meanwhile, its loss per share narrowed to $1.37 from $1.74 posted in the same period last year.